Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate

Nobuyuki Matoba, Brian C. Geyer, Jacquelyn Kilbourne, Annette Alfsen, Morgane Bomsel, Tsafrir Leket-Mor

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

CTB-MPR649-684 is a translational fusion protein consisting of the cholera toxin B subunit and a 36-residue peptide, MPR649-684, corresponding to the conserved membrane proximal ectodomain of gp41. CTB-MPR649-684 was previously shown to induce HIV-1 transcytosis-blocking antibodies in mice. In this report, we describe an effective immunization regimen for this novel anti HIV-1 vaccine-candidate. Bacterially-produced CTB-MPR649-684 was intranasally and/or intraperitoneally administered to investigate several prime-boost heterologous route immunization regimens. Mucosal priming with the adjuvant cholera toxin elicited significant levels of vaginal IgA and serum IgG specific to MPR649-684. Systemic boosting after mucosal priming enhanced the levels of serum and mucosal antibodies. Systemic priming induced a strong serum anti-MPR649-684 IgG response, which was efficiently recalled and augmented by either systemic or mucosal boosting. However, this regimen was less effective in inducing secretory anti-MPR649-684 IgA. The serum anti-MPR649-684 IgG subtype profile revealed that both IgG1 and IgG2a were induced in all the immunization regimens, and that mucosal co-administration of cholera toxin shifted the bias to the latter subtype. We concluded that, of the various immunization regimens examined here, mucosal priming with adjuvant followed by systemic boosting exhibited the best response in respect to either systemic or mucosal anti-MPR649-684 antibodies. Most importantly, mucosal antibodies elicited by this regimen significantly inhibited HIV-1 transcytosis in a human tight epithelium model.

Original languageEnglish (US)
Pages (from-to)5047-5055
Number of pages9
JournalVaccine
Volume24
Issue number23
DOIs
StatePublished - Jun 5 2006

Fingerprint

AIDS Vaccines
Subunit Vaccines
Humoral Immunity
humoral immunity
cholera toxin
Cholera Toxin
Immunization
immunization
Immunoglobulin G
Human immunodeficiency virus 1
physiological transport
vaccines
Transcytosis
HIV-1
antibodies
Serum
Immunoglobulin A
adjuvants
Antibodies
Mucosal Administration

Keywords

  • Antibodies
  • HIV-1 transmission
  • Mucosal vaccination

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate. / Matoba, Nobuyuki; Geyer, Brian C.; Kilbourne, Jacquelyn; Alfsen, Annette; Bomsel, Morgane; Leket-Mor, Tsafrir.

In: Vaccine, Vol. 24, No. 23, 05.06.2006, p. 5047-5055.

Research output: Contribution to journalArticle

Matoba, Nobuyuki ; Geyer, Brian C. ; Kilbourne, Jacquelyn ; Alfsen, Annette ; Bomsel, Morgane ; Leket-Mor, Tsafrir. / Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate. In: Vaccine. 2006 ; Vol. 24, No. 23. pp. 5047-5055.
@article{2d7f4ba2e58b4443b19441f11e015543,
title = "Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate",
abstract = "CTB-MPR649-684 is a translational fusion protein consisting of the cholera toxin B subunit and a 36-residue peptide, MPR649-684, corresponding to the conserved membrane proximal ectodomain of gp41. CTB-MPR649-684 was previously shown to induce HIV-1 transcytosis-blocking antibodies in mice. In this report, we describe an effective immunization regimen for this novel anti HIV-1 vaccine-candidate. Bacterially-produced CTB-MPR649-684 was intranasally and/or intraperitoneally administered to investigate several prime-boost heterologous route immunization regimens. Mucosal priming with the adjuvant cholera toxin elicited significant levels of vaginal IgA and serum IgG specific to MPR649-684. Systemic boosting after mucosal priming enhanced the levels of serum and mucosal antibodies. Systemic priming induced a strong serum anti-MPR649-684 IgG response, which was efficiently recalled and augmented by either systemic or mucosal boosting. However, this regimen was less effective in inducing secretory anti-MPR649-684 IgA. The serum anti-MPR649-684 IgG subtype profile revealed that both IgG1 and IgG2a were induced in all the immunization regimens, and that mucosal co-administration of cholera toxin shifted the bias to the latter subtype. We concluded that, of the various immunization regimens examined here, mucosal priming with adjuvant followed by systemic boosting exhibited the best response in respect to either systemic or mucosal anti-MPR649-684 antibodies. Most importantly, mucosal antibodies elicited by this regimen significantly inhibited HIV-1 transcytosis in a human tight epithelium model.",
keywords = "Antibodies, HIV-1 transmission, Mucosal vaccination",
author = "Nobuyuki Matoba and Geyer, {Brian C.} and Jacquelyn Kilbourne and Annette Alfsen and Morgane Bomsel and Tsafrir Leket-Mor",
year = "2006",
month = "6",
day = "5",
doi = "10.1016/j.vaccine.2006.03.045",
language = "English (US)",
volume = "24",
pages = "5047--5055",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "23",

}

TY - JOUR

T1 - Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate

AU - Matoba, Nobuyuki

AU - Geyer, Brian C.

AU - Kilbourne, Jacquelyn

AU - Alfsen, Annette

AU - Bomsel, Morgane

AU - Leket-Mor, Tsafrir

PY - 2006/6/5

Y1 - 2006/6/5

N2 - CTB-MPR649-684 is a translational fusion protein consisting of the cholera toxin B subunit and a 36-residue peptide, MPR649-684, corresponding to the conserved membrane proximal ectodomain of gp41. CTB-MPR649-684 was previously shown to induce HIV-1 transcytosis-blocking antibodies in mice. In this report, we describe an effective immunization regimen for this novel anti HIV-1 vaccine-candidate. Bacterially-produced CTB-MPR649-684 was intranasally and/or intraperitoneally administered to investigate several prime-boost heterologous route immunization regimens. Mucosal priming with the adjuvant cholera toxin elicited significant levels of vaginal IgA and serum IgG specific to MPR649-684. Systemic boosting after mucosal priming enhanced the levels of serum and mucosal antibodies. Systemic priming induced a strong serum anti-MPR649-684 IgG response, which was efficiently recalled and augmented by either systemic or mucosal boosting. However, this regimen was less effective in inducing secretory anti-MPR649-684 IgA. The serum anti-MPR649-684 IgG subtype profile revealed that both IgG1 and IgG2a were induced in all the immunization regimens, and that mucosal co-administration of cholera toxin shifted the bias to the latter subtype. We concluded that, of the various immunization regimens examined here, mucosal priming with adjuvant followed by systemic boosting exhibited the best response in respect to either systemic or mucosal anti-MPR649-684 antibodies. Most importantly, mucosal antibodies elicited by this regimen significantly inhibited HIV-1 transcytosis in a human tight epithelium model.

AB - CTB-MPR649-684 is a translational fusion protein consisting of the cholera toxin B subunit and a 36-residue peptide, MPR649-684, corresponding to the conserved membrane proximal ectodomain of gp41. CTB-MPR649-684 was previously shown to induce HIV-1 transcytosis-blocking antibodies in mice. In this report, we describe an effective immunization regimen for this novel anti HIV-1 vaccine-candidate. Bacterially-produced CTB-MPR649-684 was intranasally and/or intraperitoneally administered to investigate several prime-boost heterologous route immunization regimens. Mucosal priming with the adjuvant cholera toxin elicited significant levels of vaginal IgA and serum IgG specific to MPR649-684. Systemic boosting after mucosal priming enhanced the levels of serum and mucosal antibodies. Systemic priming induced a strong serum anti-MPR649-684 IgG response, which was efficiently recalled and augmented by either systemic or mucosal boosting. However, this regimen was less effective in inducing secretory anti-MPR649-684 IgA. The serum anti-MPR649-684 IgG subtype profile revealed that both IgG1 and IgG2a were induced in all the immunization regimens, and that mucosal co-administration of cholera toxin shifted the bias to the latter subtype. We concluded that, of the various immunization regimens examined here, mucosal priming with adjuvant followed by systemic boosting exhibited the best response in respect to either systemic or mucosal anti-MPR649-684 antibodies. Most importantly, mucosal antibodies elicited by this regimen significantly inhibited HIV-1 transcytosis in a human tight epithelium model.

KW - Antibodies

KW - HIV-1 transmission

KW - Mucosal vaccination

UR - http://www.scopus.com/inward/record.url?scp=33646872613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646872613&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.03.045

DO - 10.1016/j.vaccine.2006.03.045

M3 - Article

VL - 24

SP - 5047

EP - 5055

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 23

ER -